New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 2, 2014
09:20 EDTCVX, NTRI, BCOR, SREV, SQI, BIRT, RXII, INVN, IMMU, OPEN, AVNR, ISRG, SQNM, MRK, ECYT, RBS, AXLOn The Fly: Pre-market Movers
UP AFTER EARNINGS: Royal Bank of Scotland (RBS), up 9%... Sequenom (SQNM), up 8.2%... Nutrisystem (NTRI), up 11.5%... American Axle (AXL), up 2.9%. ALSO HIGHER: Wynn Resorts (WYNN), up 4% after earnings, shares upgraded at Sterne Agee... Avanir (AVNR), up 3.7% after upgraded at Mizuho... RXi Pharmaceuticals (RXII), up 27.4% after announcing results from study of RXI-109... Intuitive Surgical (ISRG), up 4% after announcing accelerated share repurchase. DOWN AFTER EARNINGS: Chevron (CVX), down 1%... OpenTable (OPEN), down 3.4%... Actuate (BIRT), down 18.2%... SciQuest (SQI), down 20%... ServiceSource (SREV), down 15.2%. ALSO LOWER: Endocyte (ECYT), down 60% after announcing DSMB recommends vintafolide PROCEED trial be stopped. The drug is being developed in partnership with Merck (MRK)... Immunomedics (IMMU), down 16% after filing to sell $30M worth of common stock in a spot secondary offering... InvenSense (INVN), down 9.3% after downgraded at Needham following the company's Q4 earnings report... Blucora (BCOR), down 10% after earnings, downgrade at Craig-Hallum.
News For CVX;RBS;ECYT;MRK;SQNM;ISRG;AVNR;OPEN;IMMU;INVN;RXII;BIRT;SQI;SREV;BCOR;NTRI;AXL From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | all recent news | >>
September 22, 2014
07:23 EDTRBSReport says Julius Baer mulling RBS unit acquisition, Reuters says
A report from German newspaper Sonntagsblick noted that Julius Baer (JBAXY) CEO Boris Collardi said that the company is contemplating an acquisition agreement for Royal Bank of Scotland's (RBS) Coutts International, according to Reuters, citing comments from Collardi in the report. Collardi said that the Swiss company is not looking to get in a bidding battle for Coutts' overseas division. Reference Link
07:05 EDTSQNMSequenom presents new data supporting accuracy of MaterniT21 test
Sequenom announced that its wholly owned subsidiary, Sequenom Laboratories, presented patient clinical data substantiating the performance of its MaterniT21 PLUS noninvasive prenatal test in the laboratory. An ad hoc analysis of 185,000 samples from patients at high-risk for fetal chromosome aneuploidy demonstrated stable positivity rates for trisomy 21, 18 and 13, which mirror the positivity rates found in large studies on high-risk populations utilizing invasive diagnostic procedures. Additionally, Sequenom Laboratories reported performance results from clinical testing with the MaterniT21 PLUS test with Enhanced Sequencing Series. In the ad hoc analysis based on voluntary outcomes provided by clinicians, the estimated sensitivity for trisomy 21, 18 and 13 were 99.3%, 98.3% and 97.4% respectively, and the estimated specificity was >99.9% for all three trisomies. These clinical laboratory performance data are equivalent to those published in the clinical validation studies of the MaterniT21 test. Based on these performance metrics, Sequenom Laboratories estimates that the MaterniT21 PLUS test positive predictive value for trisomy 21, 18 and 13 were 99.0%, 97.6% and 92.8% respectively, and the negative predictive value was >99.9% for all three trisomies.
06:51 EDTMRKMerck to host conference call
Subscribe for More Information
06:17 EDTAVNRAvanir implied volatility of 91 at lower end of index mean range
Subscribe for More Information
06:15 EDTRBSLloyds Banking could still leave Scotland, Daily Mail reports
Subscribe for More Information
05:59 EDTINVNInvenSense downgraded to Neutral from Outperform at RW Baird
RW Baird downgraded InvenSense (INVN) to Neutral saying a leading smartphone marker could be switching to a dual-sourcing strategy for certain components, including gyroscopes. Baird also believes competitor STMicroelectronics (STM) could be gaining market share at other smartphone makers. The firm lowered its price target for InvenSense shares to $23 from $30.
September 19, 2014
12:24 EDTCVXChevron looks to sell Hawaiian oil refinery, Bloomberg says
Subscribe for More Information
09:19 EDTINVNOn The Fly: Pre-market Movers
Subscribe for More Information
08:11 EDTINVNTriQuint chip among those in iPhone 6 Plus, iFixit reports
Subscribe for More Information
08:03 EDTINVNInvenSense, NXP, RF Micro chips included in iPhone 6, iFixit reports
Subscribe for More Information
06:46 EDTRBSStarwood Property appoints Jeffrey DiModica President effective September 18
Subscribe for More Information
September 18, 2014
08:48 EDTMRKNeogen's dairy genomic program to be marketed by Merck
Subscribe for More Information
08:37 EDTISRGIntuitive reports FDA clearance of da Vinci in benign, base of tongue procedures
Subscribe for More Information
07:52 EDTRBSUBS Chair says litigation bigger worry than stress test, Bloomberg reports
Subscribe for More Information
07:25 EDTBIRTActuate to hold a webinar
Database Trends & Applications Webinar will be held on September 18 at 2 pm. Webcast Link
06:39 EDTRBSEuropean banks take out EUR83B of loans from central bank, NY Times says
European banks agreed to take out EUR83B in low interest loans from the European Central Bank, as part of a program in which all of the funds must be loaned to businesses or individuals, or repaid to the central bank within two years, according to The New York Times. Several analysts had said that they would be disappointed if banks took out less than EUR100B in loans, but a number of analysts said that a second round of the program, due to occur in December after stress tests have been completed, may be more popular, the newspaper stated. Publicly traded European banks include Banco Santander (SAN), Barclays (BCS), Credit Suisse (CS), Deutsche Bank (DB), HSBC (HSBC), ING Groep (ING), Lloyds Banking (LYG), Royal Bank of Scotland (RBS) and UBS (UBS). Reference Link
September 17, 2014
11:57 EDTSQNMSequenom management to meet with Maxim
Meetings to be held in New York on September 22 with a group luncheon also and in Boston on September 23 hosted by Maxim.
09:33 EDTMRKMerck announced positive results from Phase 3 data for omarigliptin
Subscribe for More Information
08:31 EDTMRKMerck, Sun Pharma enter into licensing agreement for Tildrakizumab
Merck and Sun Pharmaceutical Industries, through their respective subsidiaries,announced an exclusive worldwide licensing agreement for Merck’s investigational therapeutic antibody candidate, tildrakizumab, which is currently being evaluated in Phase 3 registration trials for the treatment of chronic plaque psoriasis, a skin ailment. Under terms of the agreement, Sun Pharma will acquire worldwide rights to tildrakizumab for use in all human indications from Merck in exchange for an upfront payment of $80M. Merck will continue all clinical development and regulatory activities, which will be funded by Sun Pharma. Upon product approval, Sun Pharma will be responsible for regulatory activities, including subsequent submissions, pharmacovigilance, post approval studies, manufacturing and commercialization of the approved product. Merck is eligible to receive undisclosed payments associated with regulatory and sales milestones, as well as tiered royalties ranging from mid-single digit through teen percentage rates on sales. The transaction is subject to customary closing conditions, including the requirements under the Hart Scott-Rodino Antitrust Improvements Act.
07:08 EDTRXIIRXi Pharmaceuticals granted new patents in U.S., Europe and Japan
Subscribe for More Information
1 | 2 | 3 | 4 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use